HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection (Q33397620)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection (English)

1 reference

Europe PubMed Central

26 July 2017

microdissection

1 reference

based on heuristic

inferred from title

Cathy B Moelans

object named as

Cathy B Moelans

1

0 references

author name string

Roel A de Weger

2

1 reference

Europe PubMed Central

26 July 2017

Chantal Ezendam

3

1 reference

Europe PubMed Central

26 July 2017

Paul J van Diest

4

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

5 January 2009

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-4

0 references

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

An overview of laser microdissection technologies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

A fluid cover medium provides superior morphology and preserves RNA integrity in tissue sections for laser microdissection and pressure catapulting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

21 June 2018

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-4

21 January 2018

HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

31 October 2018

p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2631004

31 October 2018

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19123950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-4

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33397620&oldid=1685520399"